Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Nsclc-Patients'
Nsclc-Patients published presentations and documents on DocSlides.
Raising the Bar in the Management of Advanced/Metastatic NSCLC
by debby-jeon
Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...
SW GLH services for NSCLC – An update
by everly
Professor Rachel Butler. The genomic complexity of...
NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti
by sawyer742
Intervista a Federico . Cappuzzo. Background:. Pr...
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
David R.
by alida-meadow
Gandara. , MD. University of California, Davis . ...
NSCLC with high PD-L1 expression on tumor cells or tumor-in
by test
Intervista a Federico . Cappuzzo. Background:. P...
Comparision
by jane-oiler
of the expression of . 17-beta-hydroxysteroid . ...
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
by pasty-toler
This program will include a discussion of off-lab...
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature
by stefany-barnette
The Cancer genome atlas (TCGA) and the search for...
NSCLC: Epidemiology and disease characteristics
by scarlett
NSCLC, non-small cell lung cancer.. Lung cancer in...
Multidisciplinary approach to lung cancer
by elena
Kamil Konopka. Department of Oncology, University ...
Slides last updated:
by calandra-battersby
October 2013. There are two main types of lung . ...
Lung malignancy
by tawny-fly
Dr. Rachel Cary, FY1 Warwick Hospital. Learning ...
Slides last updated:
by stefany-barnette
October 2013 . Ferlay . J, Shin HR, Bray F, Forma...
L’algoritmo terapeutico
by calandra-battersby
attraverso . i . c. asi clinici. Giuseppe . Valma...
Estimated costs of managing treatment-related adverse
by lindy-dunigan
eventsof. . nivolumab. and . docetaxel. in the...
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
by olivia-moreira
Low TPS High TPS TPS = PD-L1 tumor proportion sco...
ASCO 2019 NSCLC - PARP & Chemotherapy
by mitsue-stanley
ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...
OMICS International welcomes submissions that are original and technically so as to serve both th
by lois-ondreau
OMICS Journals are poised in excellence by publi...
Module 13: Targeted Treatment
by disclaimercanon
of Lung Cancer . Wendi S Lee, MSN, RN, NP-C. Anne ...
Presented at the European Society for Medical Oncology 2019 Barcelona
by lucy
– 1 October, 2019 ● GSK 3377794 activate and i...
NSCLC: Staging and TNM classification
by molly
NSCLC, non-small cell lung cancer; TNM. , tumour, ...
mRNA anticancer Vaccines
by byrne
breakthrough. . approach. in . cancer. . treatm...
ALL, Acute lymphoblastic leukemia;
by HappyHippo
BCMA, B-cell maturation antigen; DLBCL, diffuse la...
Jchem applications in Medchem
by StarsAndStripes
Prediction. . and. . Data Sorting. Zhengtao. Li...
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
by adia
RecommendationLoE, GoRScreening with LDCT (low-dos...
NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM
by cecilia
NCCNCATEGORIESOFEVIDENCEANDCONSENSUSCategory1:Base...
AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie
by susan2
DisclosureStatement:Theauthorhasnothingtodisclose....
Checkpoint inhibitors for
by paisley
NSCLC. An update. Solange Peters, MD-PhD. Oncology...
Updates in the systemic treatment for lung
by madeline
cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....
FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY
by pamela
Case study 9. Provided by . Dr Qamar Ghafoor, Clin...
CLINICAL EXPERIENCE OF NSCLC in RSDM
by sophia
Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab ...
Istituto Toscano Tumori –Livorno, Italy
by payton
Federico . Cappuzzo. Istituto Toscano Tumori. Ospe...
Roberto Bianco Laboratori di Terapia Molecolare dei Tumori
by finley
Università . di Napoli “Federico II”. Innovat...
Striving for Consensus on the
by samantha
Optimal Management of Metastatic . Non-Small Cell ...
Load More...